Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 5;230(2):e405–e415. doi: 10.1093/infdis/jiad434

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 2. — Maximum local and systemic reactogenicity. Stacked bar charts of maximum (A and B) combined local (pain, tenderness, erythema, induration) and (C and D) combined systemic (malaise/fatigue, myalgia, headache, nausea, vomiting, chills, arthralgia, temperature) reactogenicity. A and C, Reactogenicity over all vaccinations among placebo (n = 10), ALVAC-HIV with 200 µg Env protein + MF59 adjuvant boost (Hi Pr + MF59, n = 50), ALVAC-HIV with 200 µg Env protein + AS01_B adjuvant boost (Hi Pr + AS01_B, n = 50), and ALVAC-HIV with 40 µg Env protein + AS01_B adjuvant boost (Lo Pr + AS01_B, n = 50). B and D, Reactogenicity over participants receiving 1 or more boost (third and fourth) vaccinations among placebo (n = 9), Hi Pr + MF59 (n = 49), Hi Pr + AS01_B (n = 49), and Lo Pr + AS01_B (n = 50). Grade 3 (severe), grade 2 (moderate), grade 1 (mild), none.